Form 4: Ocular Therapeutix Executive Donald Notman Reports Stock and Option Awards

Donald Notman, Chief Operating Officer and Chief Financial Officer of Ocular Therapeutix, reports the acquisition of restricted stock units and stock options.

Summary

• On August 29, 2024, Donald Notman, the Chief Operating Officer and Chief Financial Officer of Ocular Therapeutix, Inc., was granted 11,034 restricted stock units (RSUs) under the company's 2021 Stock Incentive Plan.
• These RSUs will vest over three years, with one-third vesting on the one-year anniversary of the grant date and subsequent one-third portions vesting annually thereafter, contingent upon continued service to the Corporation.
• Notman also acquired 33,602 stock options with an exercise price of $8.56, vesting monthly over four years starting one month after the grant date, and expiring on August 28, 2034.
• The report also indicates that Notman owns 208,988 shares of common stock, including 2,598 shares acquired through the Employee Stock Purchase Plan on June 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholders.

Positives

• The granting of RSUs and stock options to a key executive like Donald Notman can be seen as an incentive to align his interests with the long-term success of Ocular Therapeutix.
• The vesting schedules encourage continued service and commitment to the company.

Future Outlook

The vesting schedules of the RSUs and stock options suggest a focus on long-term performance and retention of key personnel.

Industry Context

Stock and option grants are a common practice in the pharmaceutical and biotech industries to incentivize executives and align their interests with shareholders. These grants are designed to reward performance and encourage long-term commitment to the company's goals.

Comparison to Industry Standards

• Equity compensation practices vary across the biotech industry, but grants of RSUs and stock options are standard.
• Companies like Alnylam Pharmaceuticals and Vertex Pharmaceuticals also use similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grants as a reflection of the company's commitment to rewarding key personnel.

Key Dates